BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37216734)

  • 1. Successful treatment of advanced squamous cell carcinoma arising from mature cystic teratoma of the ovary with homologous recombination deficiency: A case report.
    Tamura R; Yamaguchi M; Kitani Y; Nishikawa N; Kawasaki T; Kikuchi A
    Int J Surg Case Rep; 2023 Jun; 107():108329. PubMed ID: 37216734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Squamous cell carcinoma arising from a mature cystic teratoma of the ovary: Successful treatment with carboplatin, paclitaxel, and bevacizumab.
    Fukase M; Ohta T; Watanabe N; Suzuki Y; Seino M; Sudo T; Nagase S
    Gynecol Oncol Rep; 2020 Nov; 34():100632. PubMed ID: 32964091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olaparib: A Review as First-Line Maintenance Therapy in Advanced Ovarian Cancer.
    Paik J
    Target Oncol; 2021 Nov; 16(6):847-856. PubMed ID: 34623572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer.
    Arora S; Balasubramaniam S; Zhang H; Berman T; Narayan P; Suzman D; Bloomquist E; Tang S; Gong Y; Sridhara R; Turcu FR; Chatterjee D; Saritas-Yildirim B; Ghosh S; Philip R; Pathak A; Gao JJ; Amiri-Kordestani L; Pazdur R; Beaver JA
    Oncologist; 2021 Jan; 26(1):e164-e172. PubMed ID: 33017510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mature Cystic Teratoma of the Ovary Transforms into Squamous Cell Carcinoma: A Case Report.
    Jeong CH
    J Menopausal Med; 2023 Dec; 29(3):146-149. PubMed ID: 38230600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of combined use of macrophage colony-stimulating factor and squamous cell carcinoma antigen as a selective diagnostic marker for squamous cell carcinoma arising in mature cystic teratoma of the ovary.
    Suzuki M; Tamura N; Kobayashi H; Ohwada M; Terao T; Sato I
    Gynecol Oncol; 2000 Jun; 77(3):405-9. PubMed ID: 10831350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Squamous cell carcinoma in mature cystic teratoma of the ovary induced by human papillomavirus 16 infection: A case report and literature review.
    Shi Z; Yang L; Bian C
    Medicine (Baltimore); 2022 Sep; 101(38):e30667. PubMed ID: 36197169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Squamous cell carcinoma arising from mature cystic teratoma of the ovary.
    Chiang AJ; La V; Peng J; Yu KJ; Teng NN
    Int J Gynecol Cancer; 2011 Apr; 21(3):466-74. PubMed ID: 21430455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Driver Mutational Landscape of Ovarian Squamous Cell Carcinomas Arising in Mature Cystic Teratoma.
    Cooke SL; Ennis D; Evers L; Dowson S; Chan MY; Paul J; Hirschowitz L; Glasspool RM; Singh N; Bell S; Day E; Kochman A; Wilkinson N; Beer P; Martin S; Millan D; Biankin AV; McNeish IA;
    Clin Cancer Res; 2017 Dec; 23(24):7633-7640. PubMed ID: 28954785
    [No Abstract]   [Full Text] [Related]  

  • 10. Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis.
    Cadoo K; Simpkins F; Mathews C; Liu YL; Provencher D; McCormick C; ElNaggar AC; Altman AD; Gilbert L; Black D; Kabil N; Bennett J; Munley J; Aghajanian C
    Gynecol Oncol; 2022 Sep; 166(3):425-431. PubMed ID: 35803835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A rare case of microinvasive squamous cell carcinoma arising in mature cystic teratoma of the ovary.
    Togami S; Kawamura T; Kamio M; Douchi T
    Eur J Gynaecol Oncol; 2016; 37(3):420-2. PubMed ID: 27352578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Large cell neuroendocrine carcinoma arising in mature cystic teratoma: a case report and review of the literature.
    Miyamoto M; Takano M; Goto T; Kato M; Sasaki N; Furuya K
    Eur J Gynaecol Oncol; 2012; 33(4):414-8. PubMed ID: 23091901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial.
    Pujade-Lauraine E; Brown J; Barnicle A; Wessen J; Lao-Sirieix P; Criscione SW; du Bois A; Lorusso D; Romero I; Petru E; Yoshida H; Vergote I; Colombo N; Hietanen S; Provansal M; Schmalfeldt B; Pignata S; Martín Lorente C; Berton D; Runnebaum IB; Ray-Coquard I
    JCO Precis Oncol; 2023 Jan; 7():e2200258. PubMed ID: 36716415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiotherapy for persistent malignant transformation from mature cystic teratoma of the ovary.
    Yoshida K; Kajiyama H; Utsumi F; Mitsui H; Shibata K; Kikkawa F
    J Obstet Gynaecol Res; 2016 May; 42(5):584-588. PubMed ID: 26889642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial.
    Capoluongo ED; Pellegrino B; Arenare L; Califano D; Scambia G; Beltrame L; Serra V; Scaglione GL; Spina A; Cecere SC; De Cecio R; Normanno N; Colombo N; Lorusso D; Russo D; Nardelli C; D'Incalci M; Llop-Guevara A; Pisano C; Baldassarre G; Mezzanzanica D; Artioli G; Setaro M; Tasca G; Roma C; Campanini N; Cinieri S; Sergi A; Musolino A; Perrone F; Chiodini P; Marchini S; Pignata S
    ESMO Open; 2022 Oct; 7(5):100585. PubMed ID: 36156447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of human papillomavirus in squamous cell carcinoma arising from dermoid cysts.
    Chiang AJ; Chen DR; Cheng JT; Chang TH
    Taiwan J Obstet Gynecol; 2015 Oct; 54(5):559-66. PubMed ID: 26522111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis of squamous cell carcinoma arising from mature cystic teratoma of the ovary.
    Kikkawa F; Nawa A; Tamakoshi K; Ishikawa H; Kuzuya K; Suganuma N; Hattori S; Furui K; Kawai M; Arii Y
    Cancer; 1998 Jun; 82(11):2249-55. PubMed ID: 9610706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor.
    Tymon-Rosario JR; Manara P; Manavella DD; Bellone S; Hartwich TMP; Harold J; Yang-Hartwich Y; Zipponi M; Choi J; Jeong K; Mutlu L; Yang K; Altwerger G; Menderes G; Ratner E; Huang GS; Clark M; Andikyan V; Azodi M; Schwartz PE; Alexandrov LB; Santin AD
    Gynecol Oncol; 2022 Jul; 166(1):117-125. PubMed ID: 35599167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case report: Response to platinum agents and poly (adenosine diphosphate-ribose) polymerase inhibitor in a patient with BRCA1 c.5096G>A (R1699Q) intermediate-risk variant.
    Saito A; Tanioka M; Hirata M; Watanabe T; Odaka Y; Shimoi T; Sudo K; Noguchi E; Ishikawa M; Yonemori K
    Cancer Treat Res Commun; 2022; 32():100587. PubMed ID: 35696850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homologous recombination deficiency real-time clinical assays, ready or not?
    Fuh K; Mullen M; Blachut B; Stover E; Konstantinopoulos P; Liu J; Matulonis U; Khabele D; Mosammaparast N; Vindigni A
    Gynecol Oncol; 2020 Dec; 159(3):877-886. PubMed ID: 32967790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.